AbstractAbstract
[en] Purpose/Objective: About (2(3)) of all cases of follicular lymphoma have rearrangement of bcl-2 MBR through t(14;18) (q32;q21). This arrangement could serve as a sensitive marker for follicular lymphoma cells. The objectives of this study are two fold: 1) To assess complete molecular response rate of stages I-III follicular lymphoma to CLI by detection of PCR amplifiable bcl-2 MBR rearrangement in the bone marrow and peripheral blood before and after CLI. 2) To assess the significance of the molecular response as a prognostic indicator. Materials and Methods: 13 patients with stages I-III follicular lymphoma were treated with CLI as a part of a prospective randomized protocol comparing CLI with chemotherapy. Bone marrow and peripheral blood samples were obtained from the patients before initiation of CLI. By using the PCR technique, the DNA sequences from the bone marrow and peripheral blood samples that flank the bcl-2 MBR involved in t(14;18) (q32;q21) were amplified. For the patients who had positive PCR result, bone marrow and blood samples were followed at regular intervals during and after CLI. The patients with negative PCR result prior to CLI did not have follow-up PCR analysis. The results of the PCR amplification were correlated with clinical findings. Results: All 13 patients achieved clinical complete response after CLI. No patient has relapsed with a median follow-up period of 11 months (range 5 to 24 months). Pretreatment PCR results are available in 13 patients for peripheral blood and in 9 patients for bone marrow. (7(13)) blood and (5(9)) bone marrow samples were PCR-positive for bcl-2 MBR rearrangement. All 5 patients with positive pretreatment bone marrow also had positive pretreatment peripheral blood. (6(7)) patients with positive pretreatment blood PCR converted to negative within 2,3,5,6,6, and 10 months from the 1st day of CLI. The 7th patient has no follow-up PCR available yet. Follow-up PCR results from the pretreatment bone-marrow-positive patients are available in only 2 out of 5 patients so far. Neither of them converted to negative at 6 months. Conclusion: It is recognized that both bone marrow and peripheral blood with PCR amplifiable bcl-2 MBR rearrangement can be converted from positive to negative after chemotherapy in patients with follicular lymphoma. Early results from our study show for the first time that peripheral blood can be converted from positive to negative after CLI. It is not yet possible to draw any conclusion about conversion of bone marrow due to the small number of patients and the short follow-up. Whether the observed conversion in the peripheral blood will have clinical significance as a prognostic indicator remains to be seen with longer follow-up
Primary Subject
Secondary Subject
Source
Copyright (c) 1995 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
International Journal of Radiation Oncology, Biology and Physics; ISSN 0360-3016; ; CODEN IOBPD3; v. 32(971); p. 216
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Besa, P.C.; Viera, A.; Delgado, J.; Besa, P., E-mail: pbesa@med.puc.cl
International Conference on Advances in Radiation Oncology (ICARO). Book of extended synopses2009
International Conference on Advances in Radiation Oncology (ICARO). Book of extended synopses2009
AbstractAbstract
No abstract available
Primary Subject
Source
International Atomic Energy Agency, Division of Human Health, Vienna (Austria); American Association of Physicists in Medicine (AAPM), One Physics Ellipse, College Park, MD (United States); American Brachytherapy Society (ABS), Reston, VA (United States); American Society for Radiation Oncology (ASTRO), Fairfax, VA (United States); European Society for Therapeutic Radiology and Oncology (ESTRO), Brussels (Belgium); International Association for Radiation Research (IARR), Radiation Biology Center, Kyoto University, Sakyo-ku (Japan); International Commission on Radiation Units and Measurements, Inc. (ICRU), Bethesda, MD (United States); Asia-Oceania Federation of Organizations for Medical Physics (AFOMP), Osaka University, Suita-city (Japan); Asociacion Latinoamericana de Terapia Radiante Oncologica (ALATRO), Cancun (Mexico); European Association of Nuclear Medicine (EANM), Vienna (Austria); European Federation of Organisations for Medical Physics (EFOMP), Udine (Italy); International Network for Cancer Treatment Research (INCTR), Brussels (Belgium); International Organization for Medical Physics (IOMP), Kogarah, NSW (Australia); Trans Tasman Radiation Oncology Group (TROG), Department of Radiation Oncology, Calvary Mater Newcastle, NSW (Australia); International Union Against Cancer (UICC), Geneva (Switzerland); 353 p; 2009; p. 235-236; ICARO: International Conference on Advances in Radiation Oncology; Vienna (Austria); 27-29 Apr 2009; IAEA-CN--170/180P; No abstract provided; 2 refs, 1 fig
Record Type
Report
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
Related RecordRelated Record
INIS VolumeINIS Volume
INIS IssueINIS Issue